Association of fibrotic markers with diastolic function after STEMI

Lawien Al Ali; Wouter C. Meijers; Iris E. Beldhuis; Hilde E. Groot; Erik Lipsic; Dirk J. van Veldhuisen; Adriaan A. Voors; Iwan C.C. van der Horst; Rudolf A. de Boer; Pim van der Harst

doi:10.1038/s41598-024-69926-y

Association of fibrotic markers with diastolic function after STEMI

Lawien Al Ali^*
, Wouter C. Meijers
, Iris E. Beldhuis
, Hilde E. Groot
, Erik Lipsic
, Dirk J. van Veldhuisen
, Adriaan A. Voors
, Iwan C.C. van der Horst
, Rudolf A. de Boer
, Pim van der Harst

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Downloads (Pure)

Abstract

Galectin-3 and Suppression of tumorigenicity-2 (ST2) are known markers of cardiac fibrosis. We investigated the prognostic value of fibrotic markers for the development of diastolic dysfunction and long-term outcome in patients suffering an ST-elevated myocardial infarction (STEMI). We analyzed 236 patients from the GIPS-III cohort with available echocardiographic studies and plasma measurements at hospitalization and after 4 months follow-up. Adjusted logistic mixed effects modelling revealed no association between the occurrence of diastolic dysfunction over time with abnormal plasma levels of galectin-3 and ST2. We observed no differences regarding survival outcome at follow-up of 5 years between patients with normal versus abnormal values in both galectin-3 (P = 0.75), and ST2 (P = 0.85). In conclusion, galectin-3 and sST2 were not associated with the development of diastolic dysfunction in non-diabetic patients that presented with a STEMI.

Original language	English
Article number	19122
Number of pages	11
Journal	Scientific Reports
Volume	14
Issue number	1
DOIs	https://doi.org/10.1038/s41598-024-69926-y
Publication status	Published - 18 Aug 2024

Access to Document

10.1038/s41598-024-69926-yLicence: CC BY-NC-ND

s41598-024-69926-yFinal published version, 1.33 MBLicence: CC BY-NC-ND

Cite this

@article{0691ca09e6c74a6690f58b73560ef449,

title = "Association of fibrotic markers with diastolic function after STEMI",

abstract = "Galectin-3 and Suppression of tumorigenicity-2 (ST2) are known markers of cardiac fibrosis. We investigated the prognostic value of fibrotic markers for the development of diastolic dysfunction and long-term outcome in patients suffering an ST-elevated myocardial infarction (STEMI). We analyzed 236 patients from the GIPS-III cohort with available echocardiographic studies and plasma measurements at hospitalization and after 4 months follow-up. Adjusted logistic mixed effects modelling revealed no association between the occurrence of diastolic dysfunction over time with abnormal plasma levels of galectin-3 and ST2. We observed no differences regarding survival outcome at follow-up of 5 years between patients with normal versus abnormal values in both galectin-3 (P = 0.75), and ST2 (P = 0.85). In conclusion, galectin-3 and sST2 were not associated with the development of diastolic dysfunction in non-diabetic patients that presented with a STEMI.",

author = "\{Al Ali\}, Lawien and Meijers, \{Wouter C.\} and Beldhuis, \{Iris E.\} and Groot, \{Hilde E.\} and Erik Lipsic and \{van Veldhuisen\}, \{Dirk J.\} and Voors, \{Adriaan A.\} and \{van der Horst\}, \{Iwan C.C.\} and \{de Boer\}, \{Rudolf A.\} and \{van der Harst\}, Pim",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = aug,

day = "18",

doi = "10.1038/s41598-024-69926-y",

language = "English",

volume = "14",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Association of fibrotic markers with diastolic function after STEMI

AU - Al Ali, Lawien

AU - Meijers, Wouter C.

AU - Beldhuis, Iris E.

AU - Groot, Hilde E.

AU - Lipsic, Erik

AU - van Veldhuisen, Dirk J.

AU - Voors, Adriaan A.

AU - van der Horst, Iwan C.C.

AU - de Boer, Rudolf A.

AU - van der Harst, Pim

PY - 2024/8/18

Y1 - 2024/8/18

N2 - Galectin-3 and Suppression of tumorigenicity-2 (ST2) are known markers of cardiac fibrosis. We investigated the prognostic value of fibrotic markers for the development of diastolic dysfunction and long-term outcome in patients suffering an ST-elevated myocardial infarction (STEMI). We analyzed 236 patients from the GIPS-III cohort with available echocardiographic studies and plasma measurements at hospitalization and after 4 months follow-up. Adjusted logistic mixed effects modelling revealed no association between the occurrence of diastolic dysfunction over time with abnormal plasma levels of galectin-3 and ST2. We observed no differences regarding survival outcome at follow-up of 5 years between patients with normal versus abnormal values in both galectin-3 (P = 0.75), and ST2 (P = 0.85). In conclusion, galectin-3 and sST2 were not associated with the development of diastolic dysfunction in non-diabetic patients that presented with a STEMI.

AB - Galectin-3 and Suppression of tumorigenicity-2 (ST2) are known markers of cardiac fibrosis. We investigated the prognostic value of fibrotic markers for the development of diastolic dysfunction and long-term outcome in patients suffering an ST-elevated myocardial infarction (STEMI). We analyzed 236 patients from the GIPS-III cohort with available echocardiographic studies and plasma measurements at hospitalization and after 4 months follow-up. Adjusted logistic mixed effects modelling revealed no association between the occurrence of diastolic dysfunction over time with abnormal plasma levels of galectin-3 and ST2. We observed no differences regarding survival outcome at follow-up of 5 years between patients with normal versus abnormal values in both galectin-3 (P = 0.75), and ST2 (P = 0.85). In conclusion, galectin-3 and sST2 were not associated with the development of diastolic dysfunction in non-diabetic patients that presented with a STEMI.

UR - https://www.scopus.com/pages/publications/85201401226

U2 - 10.1038/s41598-024-69926-y

DO - 10.1038/s41598-024-69926-y

M3 - Article

AN - SCOPUS:85201401226

SN - 2045-2322

VL - 14

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 19122

ER -

Association of fibrotic markers with diastolic function after STEMI

Abstract

Access to Document

Other files and links

Fingerprint

Cite this